Consensus or Controversy? Documenting and Discussing Investigators’ Approaches to the Management of Chronic Lymphocytic Leukemia

Faculty

Toby A Eyre

MBChB, DipMedEd, MRCP, MD

Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Headington, Oxford, United Kingdom

Haematology Consultant, Honorary Senior Clinical Lecturer in Haematology

Faculty

Talha Munir

PhD

Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Consultant Hematologist

Faculty

Mazyar Shadman

MD, MPH

Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington

Professor, Innovators Network Endowed Chair, Deputy Chief Medical Officer, Medical Director, Cellular Immunotherapy, Professor, Clinical Research Division

Faculty

William G Wierda

MD, PhD

The University of Texas MD Anderson Cancer Center, Houston, Texas

Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr Elihu Estey, Section Chief, Chronic Lymphocytic Leukemia, Center Medical Director, Department of Leukemia, Division of Cancer Medicine, Deputy Division Head for Clinical and Educational Affairs

Additional faculty to be announced.

Join us on Friday, December 11^th from 7:30 AM to 9:30 AM central time (8:30 AM to 10:30 AM eastern time).

MODULE 1: Front-Line Therapy for Patients with Chronic Lymphocytic Leukemia (CLL) without High-Risk Features

MODULE 2: Initial Treatment for Patients with High-Risk CLL

MODULE 3: Available Data with and Potential Role of Noncovalent Bruton Tyrosine Kinase Inhibitor Therapy for Newly Diagnosed CLL

MODULE 4: Selection and Sequencing of Therapy for Relapsed/Refractory CLL

MODULE 5: Novel Agents in Clinical Development for CLL

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Recognize the prognostic and clinical significance of various biomarkers in CLL, such as 17p deletion, TP53 mutations and IGHV gene rearrangements, and refine molecular testing algorithms for patients newly diagnosed with this disease.
• Individualize the selection of systemic therapy for patients with newly diagnosed CLL, considering risk profile, clinical presentation, coexisting medical conditions and patient preferences.
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
• Understand published research findings with Bcl-2 inhibitors in combination with anti-CD20 antibodies as first-line treatment for CLL in order to effectively inform patients about the risks and benefits of this novel strategy.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented and emerging data with this strategy for patients with newly diagnosed and relapsed/refractory (R/R) CLL.
• Appraise clinical investigator best practices for various R/R CLL management situations, and leverage this information to improve clinical decision-making.
• Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL, and appropriately discuss clinical trial participation with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
To be announced.

MODERATOR
To be announced.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeOne, and Lilly.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.